This beneficial effect was also observed in patients with low CCR4 + CD73 + expression, suggesting that TACE could offer considerable clinical advantages for HCC patients characterized by either low CCR4-T or CCR4 + CD73 + profiles. Here, NT5E is linked to hepatocellular carcinoma.